European Medicines Agency (EMA)

Avoiding medicines stalemate post Brexit

With three rounds of negotiations concluded and little agreed, the reality of a no-deal Brexit looms large over both the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA).…

Relocation of the EMA: implications for medicines regulation

On 20 November, the General Affairs Council of the European Union will officially announce the new location of the European Medicines Agency (EMA).…

Cities compete to host EMA

The European Medicines Agency (EMA) has assessed the bids of 19 cities that have applied to host its headquarters following the UK’s exit from the European Union in 2019. The final relocation decision will be made by the European Council on 20 November 2017.…

Sales of veterinary antibiotics fall across Europe

The sales of veterinary antibiotics are declining in most countries in Europe, a report from the European Medicines Agency (EMA) has found.…

UK may be out of step with Europe on clinical trials regulations after Brexit, minister accepts

UK’s future alignment with rules on clinical trials would be “subject to negotiations”, according to minister at the Department for Exiting the European Union.…

House of Commons to discuss the use of valproate in pregnancy

The UK Parliament is to hold a debate on the use of epilepsy drug valproate in pregnancy on 19 October 2017, after campaigners and MPs called for a discussion on the drug’s risk.…

EMA rates cities wanting to be its new home

International accessibility for delegates and staff, and education and employment possibilities for their families are some of the most important rating criteria.…

EMA hosts meeting to speed up patient access to new drugs

Easier access to medicines for EU citizens has taken a step forward after a first meeting of the European Medicines Agency (EMA) and European Union healthcare payers.…

PGEU sets out best practice on pharmacovigilance and risk minimisation

The Pharmaceutical Group of the European Union has published a new Best Practice Paper on Pharmacovigilance and Risk Minimisation.…

Steroid inhalers linked to increased risk of mycobacterial infection

Use of steroid inhalers for asthma and chronic obstructive pulmonary disease increases the risk of mycobacterial infections, according to a study published in the European Respiratory Journal.…